Your browser doesn't support javascript.
loading
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Arai, Sally; Arora, Mukta; Wang, Tao; Spellman, Stephen R; He, Wensheng; Couriel, Daniel R; Urbano-Ispizua, Alvaro; Cutler, Corey S; Bacigalupo, Andrea A; Battiwalla, Minoo; Flowers, Mary E; Juckett, Mark B; Lee, Stephanie J; Loren, Alison W; Klumpp, Thomas R; Prockup, Susan E; Ringdén, Olle T H; Savani, Bipin N; Socié, Gérard; Schultz, Kirk R; Spitzer, Thomas; Teshima, Takanori; Bredeson, Christopher N; Jacobsohn, David A; Hayashi, Robert J; Drobyski, William R; Frangoul, Haydar A; Akpek, Görgün; Ho, Vincent T; Lewis, Victor A; Gale, Robert Peter; Koreth, John; Chao, Nelson J; Aljurf, Mahmoud D; Cooper, Brenda W; Laughlin, Mary J; Hsu, Jack W; Hematti, Peiman; Verdonck, Leo F; Solh, Melhelm M; Norkin, Maxim; Reddy, Vijay; Martino, Rodrigo; Gadalla, Shahinaz; Goldberg, Jenna D; McCarthy, Philip L; Pérez-Simón, José A; Khera, Nandita; Lewis, Ian D; Atsuta, Yoshiko.
Afiliação
  • Arai S; Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California.
  • Arora M; Division of Hematology, Oncology and Transplant, University of Minnesota Medical Center, Minneapolis, Minnesota.
  • Wang T; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Spellman SR; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.
  • He W; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Couriel DR; Division of Hematology/Oncology, The University of Michigan, Ann Arbor, Michigan.
  • Urbano-Ispizua A; Division of Hematology/Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Cutler CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bacigalupo AA; Department of Hematology, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Battiwalla M; Branch of Hematology, National Heart Lung and Blood Institute, Bethesda, Maryland.
  • Flowers ME; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington.
  • Juckett MB; Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
  • Lee SJ; Divison of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Loren AW; Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania.
  • Klumpp TR; Divison of Bone Marrow Transplantation, Temple Bone Marrow Transplant Program, Philadelphia, Pennsylvania.
  • Prockup SE; Divison of Bone Marrow Transplant, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ringdén OT; Division of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.
  • Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Socié G; Division of Hematology, Hôpital Saint Louis, Paris, France.
  • Schultz KR; Department of Pediatric Hematology/Oncology/BMT, British Columbia's Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Spitzer T; Department of Bone Marrow Transplant-Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Teshima T; Kyushu University Hospital, Fukuoka, Japan.
  • Bredeson CN; Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Jacobsohn DA; Division of Blood and Marrow Transplantation Center for Cancer and Blood Disorders, Children's National Health Systems, Washington, DC.
  • Hayashi RJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Drobyski WR; Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Frangoul HA; Division of Hematology-Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Akpek G; Section of Hematology Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.
  • Ho VT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lewis VA; Departments of Oncology, Paediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
  • Gale RP; Division of Experimental Medicine, Department of Medicine, Hematology Research Centre, Imperial College London, London, United Kingdom.
  • Koreth J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chao NJ; Division of Cell Therapy and Hematologica, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Aljurf MD; Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
  • Cooper BW; Department of Medicine-Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, Ohio.
  • Laughlin MJ; Medical Director, Cleveland Cord Blood Center, Cleveland, Ohio.
  • Hsu JW; Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, Florida.
  • Hematti P; Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
  • Verdonck LF; Department of Internal Medicine, Isala Clinics, Zwolle, Netherlands.
  • Solh MM; Florida Center for Cellular Therapy, Florida Hospital, Orlando, Florida.
  • Norkin M; Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, Florida.
  • Reddy V; Division of Hematology/Oncology, University of Florida, Gainesville, Florida.
  • Martino R; Department of Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Gadalla S; Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland.
  • Goldberg JD; Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • McCarthy PL; Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.
  • Pérez-Simón JA; Department of Hematology, Instituto de Biomedicina de Sevilla, Seville, Spain.
  • Khera N; Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.
  • Lewis ID; Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan.
Biol Blood Marrow Transplant ; 21(2): 266-74, 2015 Feb.
Article em En | MEDLINE | ID: mdl-25445023
ABSTRACT
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Tipos_de_cancer / Outros_tipos / Tratamento / Transplante_de_medula_ossea Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide Aguda / Transplante de Medula Óssea / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged / Newborn Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Mortalidade / Geral / Tipos_de_cancer / Outros_tipos / Tratamento / Transplante_de_medula_ossea Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide Aguda / Transplante de Medula Óssea / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged / Newborn Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article